isotretinoin

(redirected from Amnesteem)
Also found in: Medical.
Related to Amnesteem: isotretinoin, Claravis, Sotret

i·so·tre·ti·noin

 (ī′sō-trĕt′n-oin′)
n.
A synthetic isomer of retinoic acid that inhibits sebaceous gland secretion and is used in the treatment of severe nodular acne. It can cause birth defects if taken during pregnancy.

[iso- + tretinoin, retinoic acid (t(rans)- + retino(ic acid) + -in).]

isotretinoin

(ˌaɪsəʊtrəˈtɪnəʊɪn)
n
(Pharmacology) a drug related to vitamin A, used to treat severe acne that has failed to respond to other treatment
Translations

isotretinoin

n isotretinoína
Mentioned in ?
References in periodicals archive ?
Three versions of isotretinoin currently are on the market: Amnesteem, Sotret, and Claravis.
Isotretinoin is marketed under the names Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan and has been used to treat severe acne since the 1980s.
The FDA's listing will appear for searches for the drug under any of its four names, which include the Accutane brand name and generic versions Amnesteem, Claravis and Sotret.
Isotrentinoin (Accutane, Amnesteem, Claravis, Topical Acne Product Sotret) Selenium Sulfide Topical Antiseborrheic Table 3.
A total of 19 pregnancies have been reported in patients on generic isotretinoin products since they have become available, with 18 reported for Amnesteem (Bertek), one for Claravis (Barr), and none for Sotret (Ranbaxy).
A total of 19 pregnancies have been reported in patients on generic isotretinoin products since they became available, with 18 reported for Amnesteem (Bertek), one for Claravis (Barr), and none for Sotret (Ranbaxy).
Amnesteem, the branded generic version of isotretinoin approved in November 2002 by the FDA, has a similar pregnancy prevention program.
Amnesteem, the branded generic version of isotretinoin approved in November 2002 by the FDA, has a similar pregnancy prevention program, the System to Prevent Isotretinoin Related Issues of Teratogenicity (SPIRIT).
By midmonth, supplies of Amnesteem were already on their way to wholesalers.
By mid-month, supplies of Amnesteem were already on their way to wholesalers.
Over 50% of the increase in Brand Segment net revenues resulted from Amnesteem, which was launched in late fiscal 2003, with the remainder attributable to growth in the existing portfolio of products.